{
    "clinical_study": {
        "@rank": "105854", 
        "arm_group": [
            {
                "arm_group_label": "sovaprevir 200 mg/ACH-3102 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "sovaprevir 200 mg capsule QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + weight-based ribavirin BID"
            }, 
            {
                "arm_group_label": "sovaprevir 400 mg/ACH-3102 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "sovaprevir 400 mg capsule QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + weight-based ribavirin BID"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for sovaprevir capsule QD + placebo for ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + placebo for weight-based ribavirin BID"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety, tolerability and efficacy of 12 weeks of treatment with sovaprevir,\n      ACH-3102 and ribavirin in GT1, treatment-naive, HCV subjects."
        }, 
        "brief_title": "Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic HCV infection documented by one of the following:\n\n          -  HCV genotype 1\n\n          -  HCV RNA > 10,000 IU/mL at screening.\n\n          -  Signed and dated written informed consent form.\n\n          -  Willing to participate in all study activities and all study requirements (including\n             effective contraception) during study period.\n\n          -  Treatment na\u00efve subjects defined as subjects who have never received pegylated\n             interferon, RBV, or a direct-acting anti-viral agent for the treatment of chronic HCV\n             infection.\n\n          -  A liver biopsy within the last 3 years without evidence of cirrhosis\n\n        Exclusion Criteria:\n\n          -  Body Mass Index (BMI) > 36.0\n\n          -  Pregnant or nursing (lactating) females, confirmed by a positive human chorionic\n             gonadotropin (HCG) laboratory test or females contemplating pregnancy\n\n          -  Participation in any interventional clinical trial within 35 days prior to first\n             study medication dose administration on Day 1\n\n          -  Known HIV-1 or HIV-2 infection/serology and/or positive Hepatitis B Surface Antigen\n             (HBsAg)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849562", 
            "org_study_id": "ACH102-007"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "sovaprevir 200 mg/ACH-3102 50 mg", 
                    "sovaprevir 400 mg/ACH-3102 50 mg"
                ], 
                "description": "NS3/4A protease inhibitor", 
                "intervention_name": "sovaprevir", 
                "intervention_type": "Drug", 
                "other_name": "ACH-0141625"
            }, 
            {
                "arm_group_label": [
                    "sovaprevir 200 mg/ACH-3102 50 mg", 
                    "sovaprevir 400 mg/ACH-3102 50 mg"
                ], 
                "description": "NS5A inhibitor", 
                "intervention_name": "ACH-3102", 
                "intervention_type": "Drug", 
                "other_name": "ACH-0143102"
            }, 
            {
                "arm_group_label": [
                    "sovaprevir 200 mg/ACH-3102 50 mg", 
                    "sovaprevir 400 mg/ACH-3102 50 mg"
                ], 
                "description": "tablets", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Ribasphere"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Ribavirin", 
                "Protease Inhibitors", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatitis C, Chronic", 
            "Genotype 1", 
            "Hepatitis C", 
            "Liver Diseases", 
            "Hepatitis, viral, human", 
            "ribavirin", 
            "antiviral agents", 
            "anti-infective agents", 
            "protease inhibitors", 
            "NS5a inhibitors"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bakersfield", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "93301"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "New Zealand: Medsafe", 
                "Australia: Therapeutic Goods Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "HCV RNA less than the limit of quantification (<LOQ), in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to those who received placebo", 
                "measure": "Determine the Incidence of Sustained Virologic Response 4 weeks (SVR4) after the completion of treatment", 
                "safety_issue": "No", 
                "time_frame": "Four weeks after the completion of treatment"
            }, 
            {
                "description": "Adverse events will be assessed for their severity and association with study drug; physical exams, laboratory values, ECGs and vital signs will be assessed and summarized as changes from baseline values.", 
                "measure": "Safety measured via adverse events; laboratory tests, ECGs, vital signs and physical exams.", 
                "safety_issue": "Yes", 
                "time_frame": "Through 12 weeks of treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849562"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the incidence of SVR8 weeks after the completion of dosing, reported as HCV RNA less than the limit of quantification (<LOQ) in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin)", 
                "measure": "Determine the incidence of sustained virologic response at 8 weeks (SVR8) following the completion of dosing", 
                "safety_issue": "No", 
                "time_frame": "8 weeks following completion of dosing"
            }, 
            {
                "description": "To determine the incidence of SVR12 weeks after the completion of dosing, reported as HCV RNA less than the limit of quantification (<LOQ) in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin)", 
                "measure": "Determine the incidence of sustained virologic response at 12 weeks (SVR12) following the completion of dosing", 
                "safety_issue": "No", 
                "time_frame": "12 weeks following completion of dosing"
            }, 
            {
                "description": "To determine the incidence of SVR24 weeks after the completion of dosing, reported as HCV RNA less than the limit of quantification (<LOQ) in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin)", 
                "measure": "Determine the incidence of sustained virologic response at 24 weeks (SVR24) following the completion of dosing", 
                "safety_issue": "No", 
                "time_frame": "24 weeks following completion of dosing"
            }, 
            {
                "description": "To determine the incidence of complete early virologic response (cEVR) at the end of the 12-week treatment period reported as HCV RNA less than the limit of quantification (<LOQ) target not detected in subjects who received active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to placebo", 
                "measure": "Determine the incidence of complete early virologic response (cEVR) at the end of the 12-week treatment period", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To determine the incidence of rapid virologic response (RVR) defined as HCV RNA less than the limit of quantification (<LOQ) target not detected at week 4 in subjects receiving active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to placebo", 
                "measure": "Determine the incidence of rapid virologic response (RVR)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "To determine the incidence of extended rapid virologic response (eRVR) defined as HCV RNA less than the limit of quantification (<LOQ) target not detected at weeks 4 and 12 in subjects receiving active treatment (sovaprevir and ACH-0143102 in combination with ribavirin) as compared to placebo", 
                "measure": "Determine the incidence of extended rapid virologic response (eRVR)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "To determine the PK/PD relationship between the combination treatment regimen (sovaprevir, ACH-0143102 and ribavirin) and virologic response", 
                "measure": "Pharmacokinetic analysis of trough samples analyzed for concentrations of sovaprevir, ACH-3102 and ribavirin from baseline through week 20.", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }
        ], 
        "source": "Achillion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Achillion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}